Welcome to our dedicated page for Altimmune news (Ticker: $ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Altimmune's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Altimmune's position in the market.
Altimmune, Inc. (Nasdaq: ALT) will report its first quarter 2024 financial results and provide a business update on May 9, 2024. Altimmune management will host a conference call to discuss the financial results and business update.
Altimmune, Inc. (Nasdaq: ALT) will be represented by Dr. Scott Harris, Chief Medical Officer, at two upcoming conferences: BTIG Obesity Health Forum and GLP-1-Based Therapeutics Summit. The presentations will focus on emerging therapeutics and the use of GLP-1s in treating MASH & Fatty Liver Disease.
